The list compiled by Alantra, an international financial services company, ranks companies according to their revenue growth over the past two years.

Richmond Pharmacology is delighted with the recognition and features in the lists top twenty at number 17. The Alantra Pharma Fast 50 is in its fifth year and was launched to recognise and celebrate successful business within the UK life sciences market.

The list includes analysis of businesses grouped into four distinct sub-sectors – Technology; Analytics, insights and communication; Pharma outsourcing; and Develop, wholesale and supply.

Richmond Pharmacology is categorised in the publication as a Contract research organisation providing services from design to delivery of early phase clinical trials.

Read the report in full

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event